Literature DB >> 32862944

EDITORIAL COMMENT.

Ahmed Ibrahim1, Serge Carrier1.   

Abstract

Entities:  

Year:  2020        PMID: 32862944      PMCID: PMC7452902          DOI: 10.1016/j.urology.2020.03.070

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


× No keyword cloud information.
This is a retrospective analysis of the comorbidities potentially present in young men with erectile dysfunction (ED) who are targeted by direct-to-consumer (DTC) internet platforms that sell PDEi-5 without comprehensive clinical evaluation. In this study, the authors analyzed 388 patients ≤40 years at an andrology clinic over a period of 3 years. As expected, they detected a significant number of comorbidities that would be missed by DTC platforms, which rely only on questionnaires for health screening. In their cohort, they found 15% rate of obesity, 20% prediabetes or diabetes, 54% dyslipidemia, and 20% hypogonadism. Additionally, a varicocele was found in 35% during the physical exam. The authors recommended that urologists may play an important role in incorporating telemedicine to enfranchise young men with evidence-based evaluation to ensure adequate medical assessment and reduce mismanagement. In an era where everything is fast, DTC telemedicine companies offer a convenience within a health care system that many patients find complex and difficult to access. It is uncertain, however, if the care provided is equivalent to a traditional in-person visit. DTC telemedicine visits may have several potential advantages – information gathering through a questionnaire before the patient is encountered; questionnaires may be consistent and comprehensive; increase efficiency when the patient is encountered. This study is one of the rare studies evaluating the potential impact of DTC internet platforms on young men diagnosed with ED which sell PDEi-5 without comprehensive clinical evaluation. We agree with the authors that DTC internet platforms are still lacking formal guidelines in the context of online media. Therefore, we strongly believe that urologists should be a crucial element in incorporating telemedicine to enfranchise young men with evidence-based evaluation to ensure adequate medical assessment and reduce mismanagement or overtreatment. Although DTC platforms are becoming a prominent part of the health care landscape of the United States, they are still not approved in many countries. Therefore, evaluating the impact of these new platforms on our patients should be better studied. As the authors acknowledge, the limitations and inconstancy of certain DTC platforms screening questionnaires without office visits could explain for ED mismanagement in the study cohort. Prospective studies would help us to identify the actual pitfalls of DTC platforms and provide corrective measures for better practice as well as help us to recommend its proper use for better clinical practice. Since the pandemic with COVID-19, we had the opportunity to use telemedicine. As a follow-up for known patients, it is a useful tool. However, in assessing a new patient, it lacks the direct interaction that enables us to have a better judgment of the patient's psychological distress that a questionnaire may not give. It would be sad and dangerous if physician judgment is replaced by a questionnaire. The lack of a physical exam will miss some comorbidities. However, if done properly, telemedicine could attract individuals that would not consult a physician usually, but allow further follow-up in person. It could be a useful tool for men's health if used properly to bring men into our offices. Time will tell us but useful guideline for telemedicine is needed as well as research. ,
  2 in total

1.  Prescriptions on Demand: The Growth of Direct-to-Consumer Telemedicine Companies.

Authors:  Tara Jain; Richard J Lu; Ateev Mehrotra
Journal:  JAMA       Date:  2019-09-10       Impact factor: 56.272

2.  Direct-to-Consumer Advertising of Prescription Drugs and the Patient-Prescriber Encounter: A Systematic Review.

Authors:  Jessica T DeFrank; Nancy D Berkman; Leila Kahwati; Katherine Cullen; Kathryn J Aikin; Helen W Sullivan
Journal:  Health Commun       Date:  2019-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.